



Eagleview Corporate Center  
665 Stockton Drive  
Exton, PA 19341  
Telephone: (610) 458-8959  
Fax: (610) 458-8249

03033707

November 12, 2004

U. S. Nuclear Regulatory Commission  
Region 1  
Division of Nuclear Materials Safety  
475 Allendale Road  
King of Prussia, PA 19406-1415

Subject: Update of License # 37-30182-01 Section 11 A


Dear Sir or Madam:

This is a request to amend the Byproduct Material License # 37-30182-01. Theodore Carver is no longer employed with Johnson & Johnson PRD and should be removed from Section 11 (A). Christian Baumann will handle supervision of his radioactive activities.

In addition, we request to add Carl Crysler as a radiation principle investigator to supervise the use of radioactive materials and/or use radioactive materials listed in Sub items 6.A - F. Enclosed is a copy of Carl's 'Application to Become a Radiation Authorized Researcher'.

Should you have any questions please contact Mr. Frajerman at (610) 458-6053.

Sincerely,

  
\_\_\_\_\_  
Jason VanBuren  
Senior Director, Operations & Planning  
Radiation Safety Officer

RECEIVED  
REGION 1  
NOV 23 AM 10:25 '04

Attachment 1: Application to Become a Radiation Authorized Researcher

136018

## PRD Cranbury/Exton Application To Become a Radiation Authorized Researcher

EMPLOYEE NAME LAST FIRST MI. DEGREE <b>CRYSLER CARL S MS</b>				JOB TITLE <b>SCIENTIST</b>	SOCIAL SECURITY NUMBER <b>201-44-2302</b>
DATE OF BIRTH <b>9/15/57</b>	SEX <input checked="" type="checkbox"/> Male <input type="checkbox"/> Female		SITE <input checked="" type="checkbox"/> Exton <input type="checkbox"/> Cranbury		
DEPARTMENT <b>IPD</b>	SUPERVISOR <b>MOLLOY</b>	OFFICE PHONE NO. <b>610.458.5284</b> <b>x6505</b>	LAB NUMBER <b>18</b>		

**Authorization requested as:**

- Radiation Principal Investigator (attach curriculum vitae (CV))  
 Associate Investigator under P.I.: \_\_\_\_\_  
 Other: \_\_\_\_\_

Select the radionuclides or ionizing radiation producing equipment that you will be using that will require you to be monitored for external radiation exposure:

X-Ray  NMR  <sup>3</sup>H  <sup>14</sup>C  <sup>32</sup>P  <sup>33</sup>P  <sup>35</sup>S  <sup>125</sup>I  Other \_\_\_\_\_

Have you ever worked with radioactive material or ionizing radiation producing equipment?  Yes  No

Have you previously been issued a whole body badge or ring TLD at PRD Cranbury/Exton? If yes, when: \_\_\_\_\_  Yes  No

Have you been employed at another company where you worked with radioactive materials and/or ionizing radiation producing equipment?  Yes  No

If yes, was your exposure monitored?  Yes  No

If yes, what method was used? (check all that apply)

whole body badge  thyroid bioassay  other \_\_\_\_\_  
 ring TLD  urine bioassay (specify)

**Detail your previous training in radiation safety:**

Where Trained:	Date of Training:	On the Job # of years	Formal Course # of hours
<b>SMITH KLINE FRENCH</b>	<b>1991</b>	<b>6</b>	<b>3</b>

## PRD Cranbury/Exton Application To Become a Radiation Authorized Researcher

Detail your previous experience with radioactive materials or ionizing radiation producing equipment.

Where Experience Was Gained:	Dates of Experience from-to:	Radionuclides and Maximum Amounts or Equipment Used:	Type of Use:
SKF	1991 - 1997	$^{125}\text{I}$ , 1mCi;  $^3\text{H}$ 4mCi	protein label  protein label

Employee has been assigned:	<input type="checkbox"/> Whole Body Badge	<input type="checkbox"/> Ring TLD	DATE ORDERED / /
-----------------------------	---	-----------------------------------	---------------------

I certify that I have read and understand the PRD Cranbury/Exton Radiation Safety Practices. I agree to abide by the conditions contained therein and any additional conditions. If I do not abide by these conditions I understand my authorization to use radioactive materials may be revoked.

EMPLOYEE SIGNATURE <i>Carl Cyde</i>	DATE 28 Sep 104
--	--------------------

SUPERVISOR SIGNATURE <i>[Signature]</i>	DATE 10 11 104
--	-------------------

RSO SIGNATURE <i>[Signature]</i>	DATE 11 12 104
-------------------------------------	-------------------

## Carl Crysler

2008 School Rd

Pottstown, PA 19465

W (610) 458-5264 x6505; crysler@3dp.com

### Profile

---

Pharmaceutical biochemist specializing in assay development and screening of protein therapeutics, organic drug molecules, and prodrugs in biological media. Supervised, conducted, and reported enzymatic and protein receptor screens, pharmacokinetic studies, and specialized studies in support of discovery and development programs.

- Assay development
- ELISA/ECLIA
- Enzymatic assays
- HPLC assays
- Cell-based assays
- Protein purification
- Pharmacokinetics
- Group supervisor
- GLP management

### Professional Experience

---

Scientist, Department of Discovery Biology, Johnson & Johnson, 2003-present  
Research Scientist, Department of Enzymology, 3-Dimensional Pharmaceuticals, 1999-2003  
Associate Research Scientist, Department of Enzymology, 3DP, 1997-1999

Development of ELISA and enzymatic assays (colorimetric, fluorescent) for screening of inhibitors to coagulation and cancer targets such as proteases, integrins, and kinases. Subsequent screening with these assays lead to the identification of patentable inhibitor compounds. Targets include: iNOS, Bcl-2, Bax, BAD, PAI-1, MEK, insulin receptor kinase, VEGF KDR, ckit, CDK4, CDK6, Aurora, tpl2, MK2, cfms, cmet, HDM2, FGF-D2D3, GP1bIX-vWF, factor Xa, uPA, uPA in plasma, C1s, C1r, C3a, C4d, MASP-2, thrombin, clot-bound thrombin, trypsin, plasmin, tPA, PTP-1B,  $\alpha$ V $\beta$ 3,  $\alpha$ V $\beta$ 5,  $\alpha$ 5 $\beta$ 1, GP2b3a, matriptase, DPPIV, TPO mimetic in plasma. Supervised one scientist.

SmithKline Beecham Pharmaceuticals, Swedeland, PA, 1991-1997  
Investigator, Department of Discovery, Drug Metabolism and Pharmacokinetics

Responsible for departmental development of assays for protein therapeutics in biological media. Development of enzymatic, HPLC, and immunoassays (ELISA, ECLIA) for therapeutic proteins and smaller organic drug molecules in biological media. Pharmacokinetic studies in preclinical species.

- Developed electrochemiluminescent immunoassays (ECLIA) for prinitized and humanized antibodies (anti-CD4, anti-RSV, anti-IL4, anti-IL5) in animal and human plasma that reduced analysis time by 30-50% compared to ELISA. Transferred ECLIA methods to two contract houses. These ECLIAs replaced most departmental ELISA methods.
- Developed ELISAs in plasma for preclinical and clinical analysis of prinitized and humanized mAbs and therapeutic proteins (anti-malarial, anti-RSV, anti-CD4 IgG1 and IgG4, anti-IL4, anti-IL5, soluble complement receptor).
- HPLC reversed-phase and size exclusion assays in plasma (radiolabeled IL5/anti-IL5 complexes, plasma esterase activities, prodrug conversion assays, glucuronidation studies, 5-

- lipoxygenase inhibitors, angiotensin II antagonists, insulin sensitizers, HIV protease inhibitors, rapamycin analogs, endothelin receptor antagonists, growth hormone releasing peptide).
- Preclinical pharmacokinetic studies (includes formulation studies, hepatic portal/intravenous switch infusions crossed over to intraduodenal infusion, ramp infusions).
  - Pharmacokinetic/biodistribution studies by flow cytometry of anti-CD4 mAbs in human CD4+ transgenic mice.
  - Cell-based assays in plasma (bacterial anti-fibronectin binding assay, red blood cell hemolytic assays for soluble complement receptor and total complement activity).
  - Protein radiolabeling and radiolabeled pharmacokinetic studies.
  - Departmental representative for discovery programs.
  - Supervised two scientists.
  - Authored departmental SOPs for GLP compliance.

**SmithKline Beecham Pharmaceuticals, Swedeland, PA, 1987-1991**  
**Senior Scientist, Drug Metabolism and Pharmacokinetics**

- Developed two ELISA methods for soluble CD4 (sT4) in preclinical and clinical species.
- Established a dedicated BL-2 laboratory for analysis of sT4 in plasma and urine from HIV-infected patients.
- Programmed a robotic workstation for analysis of sT4 in HIV-infected plasma.
- Enzymatic assay development and inactivation studies of third generation fibrinolytic protein therapeutics in human plasma.
- Preclinical pharmacokinetic studies.
- Supervised two scientists.

**SmithKline Beckman, Swedeland, PA, 1985-1987**  
**Scientist, Drug Metabolism and Pharmacokinetics**

- Developed enzymatic assays for tissue plasminogen activator (tPA) in plasma from clinical and preclinical species (involved inactivation of species-specific tPA inhibitors).
- Preclinical pharmacokinetic studies.

**Biogen Research Corporation, Cambridge, MA, 1983-1984**  
**Technician II**

Development of purification procedures/pilot plant scale-up processes for tPA derived from CHO cells, and for IL-2 derived from recombinant bacteria. Experience included analytical and preparative LC and HPLC, GMP, and clean room procedures. Supervised five technicians.

**Pennsylvania State University, University Park, PA, 1979-1980**  
**Research Associate, Laboratory of Professor Joseph Villafranca.**

Bacterial fermentation, purification, and characterization of GMP Synthetase. Developed enzymatic and HPLC assays to delineate the kinetic mechanism of GMP Synthetase. Investigations included substrate stereochemistry, metal ion binding affinity, fluorescent and EPR spectroscopy.

**Education**

---

**M. S., Biochemistry, Pennsylvania State University, University Park, PA, 1984**  
**B. S., Biochemistry, Pennsylvania State University, University Park, PA, 1979**

## Publications

---

Juan Jose Marugan, Kristin D. Haslow, Carl Crysler. Design, synthesis, and biochemical evaluation of novel  $\alpha V\beta 3$  integrin ligands. *Bioorg Med Chem Lett*, **14** (12), 4553-4555 (2004).

Jeremy M. Travins, Nalin Subasinghe, Ehab M. Khalil, Farah Ali, Heather Rae Hufnagel, Shelley K. Ballentine, Micheal D. Gaul, Richard M. Soll, Maxwell D. Cummings, Renee L. DesJarlais, Carl Crysler, Nisha Ninan, and Roger Bone. Synthesis and SAR of 4-Biarylsulfonyl-thiopheneamidines as Inhibitors of the Complement Protease C1s. Manuscript in preparation.

Ehab M. Khalil, Nalin Subasinghe, Jeremy M. Travins, Farah Ali, Heather Rae Hufnagel, Shelley K. Ballentine, Micheal D. Gaul, Richard M. Soll, Maxwell D. Cummings, Renee L. DesJarlais, Carl Crysler, Nisha Ninan, and Roger Bone. Lead Optimization of 4-Arylsulfonyl Thiophene Amidines: A Potent and Selective Class of Complement C1s Inhibitors. Manuscript in preparation.

Subasinghe, N.L., Ali, F., Illig, C., Rudolph, M.J., Klein, S., Khalil, E., Soll, R., Bone, R., Spurlino, J., DesJarlais, R., Crysler, C., Cummings, M.D., Morris Jr., P.E., Kilpatrick, J.M., Babu, Y.S. A novel series of potent and selective small molecule inhibitors of the complement component C1s. *Bioorg Med Chem Lett*, **14** (12), 3043-3047 (2004).

Lu, T., Markotan, T., Coppo, F., Tomczuk, B., Crysler, C., Eisennagel, S., Spurlino, J., Bone, R. Oxyguanidines: Part 2. Discovery of a Novel Orally Active Thrombin Inhibitor through Structure-Based Drug Design and Parallel Synthesis. *Bioorganic & Medicinal Chemistry Letters*, **14**, 3727-3731 (2004).

Tomczuk, B., Lu, T., Soll, R., Fedde, C., Wang, A., Murphy, L., Crysler, C., Dasgupta, M., Eisennagel, S., Spurlino, J., Bone, R. Oxyguanidines: Application to Non-peptide Phenyl-based Thrombin Inhibitors. *Bioorganic & Medicinal Chemistry Letters*, **13** (8), 1495-1498 (2003).

Subasinghe, N.L., Illig, C., Hoffman, J., Rudolph, M.J., Wilson, K.J., Soll, R., Randle, T., Green, D., Lewandowski, F., Zhang, M., Bone, R., Spurlino, J., DesJarlais, R., Deckman, I., Molloy, C.J., Manthey, C., Zhou, Z., Sharp, C., Maguire, D., Crysler, C., Grasberger, B. Structure-based design, synthesis, and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. *Bioorg Med Chem Lett*, **11**, 1379-1382 (2001).

Newman, R., Hariharan, K., Reff, M., Anderson, D. R., Braslawsky, G., Santoro, D., Hanna, N., Bugelski, P. J., Brigham-Burke, M., Crysler, C., Gagnon, R. C., Dal Monte, P., Doyle, M. L., Hensley, P. C., Reddy, M. P., Sweet, R. W., and Truneh, A. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but not deplete CD4+ T cells in chimpanzees. *Clinical Immunol*, **98** (2), 164-74 (2001).

Davis, C. B., Crysler, C. S., Boppana, V. K., Fong, K.-L., Joseph, G. L., Garver, E. M., Urbanski, J. J., Yachetti, S., Macia, R. A., Dulik, D. M., and Rhodes, G. R. Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration. *Drug Metab. and Disp.*, **22** (1), 1994.

Qian, M., Swagler, A. R., Fong, K.-L. L., Crysler, C. S., Metha, M., Gallo, J. M. Pharmacokinetic evaluation of drug interactions with anti-HIV drugs. V: Effect of soluble CD4 (sT4) on 2', 3'-dideoxycytidine (ddC) kinetics in monkeys. *Drug Metab. and Disp.*, 20, 396-401, 1992.

Kopia, G. A., Kopaciewicz, L. J., Fong, K.-L. L., Crysler, C. S., Boyle, K. E., and Ruffolo Jr., R. R. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog. *J. Card. Pharm.*, 12, 308-316, 1998.

Fong, K.-L. L., Crysler, C. S., Mico, B. A., Boyle, K. E., Kopia, G. A., Kopaciewicz, L. J., and Lynn, R. K. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. *Drug Metab. and Disp.*, 16, 201-206, 1988.

Von der Saal, W., Crysler, C. S., and Villafranca, J. J. Positional isotope exchange and kinetic experiments with *Escherichia coli* Guanosine-5'-monophosphate synthetase. *Biochemistry*, 24, 5343-5350, 1985.

#### Abstracts

---

Gushue, J., Leonard, K., Pan, W., Anaclerio, B., Guo, Z., DesJarlais, R., Lattanze, J., Crysler, C., Marugan, J., Manthey, C., Tomczuk, B., Lu, T., Markotan, T., Chaikin, M., Donatelli, R., Hubert, N., Eisennagel, S., Dasgupta, M., Fries, H. Non-peptide  $\alpha V\beta 3$  antagonist containing indol-1-yl propionic acids. 228<sup>th</sup> ACS National Meeting, Philadelphia, PA, August 2004.

Khalil, E., Subasinghe, N., Travins, J., Ali, F., Hufnagel H., Ballentine, S., Gaul, M., Soll, R., Cummings, M., DesJarlais, R., Crysler, C., Bone, R. Discovery and optimization of 4-biphenyl sulfonyl thiophene amidines as a novel class of potent and selective complement C1s inhibitors. 228<sup>th</sup> ACS National Meeting, Philadelphia, PA, August 2004.

Travins, J., Subasinghe, N., Khalil E., Ali, F., Gushue, J., Hufnagel, H., Ballentine, S., Huang, H., Gaul, M., Bone, R., Soll, R., Crysler, C., DesJarlais, R., Cummings, M. Synthesis and SAR of some aryl- and heteroarylsulfonyl thiopheneamidines as inhibitors of the complement serine protease C1s. 228<sup>th</sup> ACS National Meeting, Philadelphia, PA, August 2004.

Tianbao Lu, Thomas Markotan, Frank Coppo, Bruce Tomczuk, Carl Crysler, Stephen Eisennagel, John Spurlino, Rich Soll and Roger Bone. Oxyguanidines: Discovery of a Novel Orally Active Thrombin Inhibitor through Structure-Based Drug Design and Parallel Synthesis. 226<sup>th</sup> ACS National Meeting in New York, NY, September 2003.

Farah Ali, Carl Illig, M. Jonathan Rudolph, Scott Klein, Ehab Khalil, Richard Soll, Roger Bone, John Spurlino, Renee DesJarlais, Carl Crysler, John Kilpatrick, Yarlagadda Babu, and Nalin L. Subasinghe. Synthesis and Biological Activity of Selective Small Molecule Inhibitors of C1s. 226<sup>th</sup> National ACS Meeting, New York, NY, September 2003.

T. Lu, B. Tomczuk, R. M. Soll, C. Fedde, A. Wang, L. Murphy, C. Crysler, M. Dasgupta, S. Eisennagel, J. Spurlino, R. Bone. Oxyguanidines: Application to nonpeptidic phenyl-based thrombin inhibitors. 224<sup>th</sup> National American Chemical Society, Boston, MA. August, 2002.

Manthey, C. L., Lee, Y.-K., Wang, A., Crysler, C., Zhao, S., Lee, Y.-K., Bone, R. F., Soll, R. M., and Tomczuk, B. Characterization of o-guanidines as novel  $\alpha V\beta 3$  inhibitors. *Proc. Am. Assoc. Cancer Res.*, 42, 368, 2001.

Green, D. W., Manthey, C. L., Crysler, C. S., Zhou, Z., Lee, Y.-K., Molloy, C. J., Tomczuk, B. E., Dhanoa, D. S., Soll, R. M., and Bone, R. F. Identification of novel small molecule vitronectin receptor ( $\alpha V\beta 3$  integrin) antagonists. *Molecular Targets and Cancer Therapeutics (AACR)*, Washington, DC. November, 1999.

Boyle, K., Davis, C., Crysler, C., Urbanski, J. J., and Fong, K.-L. L., Western blot analysis of therapeutic proteins in human, monkey, and rat plasma and urine. Presented at the annual meeting of The Electrophoresis Society, Chapel Hill, NC. June, 1992.

Smith III, E. F., DiMartino, M. J., Davis, P. A., Egan, J. W., Hillegass, L. M., Brown, K., Crysler, C., and Fong, K.-L. L. Human soluble complement receptor 1 (sCR1) therapeutically reduces myocardial ischemic/reperfusion injury. *American Heart Association 64th Scientific Session*, Anaheim, CA. November, 1991.

Seaman, M. B., Schrader, D., Baldoni, J., Crysler, C., Fong, K., Mai, S., Moore, D., Anders, C., Leary, J., and Peterson, J. Comparison of activity assays of a soluble sT4 receptor. *Sixth National AAPS Meeting*, Washington, D. C., November, 1991.

Crysler, C., Urbanski, J. J., and Fong, K.-L. L. Comparative pharmacokinetics of recombinant soluble CD4 (sT4) in rats following single intravenous, subcutaneous, intramuscular, and intraperitoneal administration. Presented at the annual meeting of ISSX, Amsterdam, The Netherlands. July, 1991.

Qian, M., Swagler, A., Mehta, M., Fong, K.-L. L., Crysler, C., Gallo, J. M. Pharmacokinetic evaluation of 2', 3'-dideoxycytidine (ddc)-soluble CD4 (sT4) drug interaction in monkeys. *Pharm. Res.*, 8: 265, 1991.

Miller-Stein, C., Crysler, C., Rhodes, G., and Boppana, V. K. A column switching high performance liquid chromatographic method using automated pre-column fluorescence derivatization for determination of a lysine-containing growth hormone releasing peptide in plasma. *Eleventh International Symposium on HPLC of Proteins, Peptides, and Polynucleotides*, Washington, D. C., October, 1991.

Boyle, K., Campbell, S., Jenkins, E., Crysler, C., and Fong, K.-L. L. Bioavailability of recombinant soluble CD4 (sT4) in cynomolgus monkeys following intramuscular (im) and subcutaneous (sc) administration. *AAPS annual meeting*, November, 1990.

Crysler, C., Boyle, K., Jonak, Z., Oka, M., Culp, J., Urbanski, J. J., and Fong, K.-L. L. Whole blood distribution and quantitation of recombinant soluble CD4 (sT4) in HIV infected plasma by single and double monoclonal based ELISAs directed to sT4 V1 and V4 regions. *Sixth International AIDS Conference*, vol. 1, p. 182, San Francisco, CA, June, 1990.

Fong, K.-L. L., Webb, D., Crysler, C., Donnelly, M., Looney, D., and Bartlett, J. Dose proportionality of subcutaneous and intravenous pharmacokinetics of recombinant soluble CD4

(sT4) in HIV infected patients. Sixth International AIDS Conference, vol. 3, p. 201, San Francisco, CA, June, 1990.

Cryslar, C., Boyle, K. E., and Fong, K.-L. L. Pharmacokinetics of recombinant soluble CD4 (sT4) in cynomolgus monkeys following intravenous administration. Fifth International AIDS Conference, Montreal, Canada. June, 1989.

Fong, K.-L. L., Cotter, L., Fujita, A., Chen, T. K., Reff, M. E., Cryslar, C. S., Boyle, K. E., Pfarr, D. S., Trill, J. J., Connors, R., Williams, D., Mico, B. A., and Shebuski, R. J. Comparative pharmacokinetics of recombinant tissue-type plasminogen activator (tPA) derived from four different cell lines. *Fibrinolysis*, 2(S1): 29, 1988.

Boyle, K. E., Carr, S. A., Cryslar, C. S., Cotter, L. M., and Fong, K.-L. L. Effects of saccharides and an ASN-448 linked glycopeptide on the pharmacokinetics of tissue-type plasminogen activator. AAPS third annual meeting, November, 1988.

Cryslar, C., and Fong, K.-L. L. A species comparison study of 1- and 2-chain tissue-type plasminogen activator inactivation in platelet rich plasma. AAPS third annual meeting, November, 1988.

Fong, K.-L. L., Boyle, K., Cryslar, C., Landi, M., Griffin, H., Mico, B., and Lynn, R. Extrahepatic metabolism of recombinant tissue-type plasminogen activator (tPA). Eleventh International Congress on Thrombosis and Haemostasis, 1987.

Fong, K.-L. L., Cryslar, C., Mico, B., Boyle, K., Kopia, G., and Lynn, R. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator (tPA) in anesthetized dogs following intravenous infusion. *Thromb. Haemostasis*, 58: 435, 1987.

#### Reports

---

Primary or contributing author of over 50 internal scientific reports at SmithKline Beecham.

This is to acknowledge the receipt of your letter/application dated

November 12, 2004, and to inform you that the initial processing which includes an administrative review has been performed.

There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information. *Amend*

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 136018.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.

BETWEEN:

License Fee Management Branch, ARM  
and  
Regional Licensing Sections

: (FOR LFMS USE)  
: INFORMATION FROM LTS  
: -----  
:  
: Program Code: 03620  
: Status Code: 0  
: Fee Category: 3M  
: Exp. Date: 20100531  
: Fee Comments: \_\_\_\_\_  
: Decom Fin Assur Req: N  
: ::

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: 3-DIMENSIONAL PHARMACEUTICALS, INC.  
Received Date: 20041123  
Docket No: 3033707  
Control No.: 136018  
License No.: 37-30182-01  
Action Type: Amendment

2. FEE ATTACHED

Amount: \_\_\_\_\_  
Check No.: \_\_\_\_\_

3. COMMENTS

Signed (S)  
Date 11/26/04

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /\_/)

1. Fee Category and Amount: \_\_\_\_\_

2. Correct Fee Paid. Application may be processed for:

Amendment \_\_\_\_\_  
Renewal \_\_\_\_\_  
License \_\_\_\_\_

3. OTHER \_\_\_\_\_  
\_\_\_\_\_

Signed \_\_\_\_\_  
Date \_\_\_\_\_